Mometasone Viatris (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress inflammatory cytokine production. This reduces swelling, mucus formation, and immune cell activity, leading to improved nasal airflow and symptom relief.

The prescribed dose of Mometasone Viatris is determined by a qualified healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mometasone Viatris in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mometasone Viatris is a high‑potency nasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency agents, it may achieve symptom control with once‑daily dosing, but individual response and tolerability can vary, so clinicians choose the most appropriate option for each patient.

Store Mometasone Viatris at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme heat to maintain potency and stability.

Mometasone Viatris is administered as a nasal spray. The patient should gently blow the nose, insert the spray tip into one nostril, close the opposite nostril, and spray the prescribed number of sprays while breathing in gently. The process is then repeated for the other nostril if directed.

Serious risks, though rare, include adrenal suppression, cataracts, glaucoma, and opportunistic fungal infections of the nasal mucosa. Patients should report persistent nosebleeds, visual changes, or signs of systemic steroid effects to their healthcare provider promptly.

Mometasone Viatris should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with active untreated nasal infections or recent nasal surgery unless advised by a physician.